Lifeboat News: The Blog – Safeguarding Humanity

A Deeper Look At Human Longevity Genes

Posted by Paul Battista in biotech/medical, life extension

Jan 30
2019

(Advances in science and public health are increasing longevity and enhancing the quality of life for people around the world. In this series of interviews with the Milken Institute Center for the Future of Aging, 14 visionaries are revealing exciting trends and insights regarding healthy longevity, sharing their vision for a better future. The Longevity Innovators interviews highlight new discoveries in biomedical and psychosocial science, as well as strategies to promote prevention and wellness for older adults. This is the last story in the series.)

Director of the Longevity Genes Project at the Albert Einstein College of Medicine, Dr. Nir Barzilai has discovered several longevity genes in humans that appear to protect centenarians against major age-related diseases. Barzilai is also co-founder of CohBar, a biotech company developing mitochondria-based therapeutics to treat diseases associated with aging. In an interview with the Milken Institute Center for the Future of Aging, Barzilai explains why some people have longevity genes and the challenges in drug design for age-related diseases:

Implantable Vagus Nerve Stimulation Device Aids Weight Loss

Posted by Paul Battista in biotech/medical

Jan 30
2019

An international team of researchers led by University of Wisconsin-Madison scientists has developed an easily implantable weight-loss device. In lab experiments, the device helped rats shed 38% of their body weight.

Researchers identify drug against the formation of metastasis

Posted by Paul Battista in biotech/medical

Jan 30
2019

The most deadly aspect of breast cancer is metastasis, cancer cells spreading throughout the body. Researchers at the University and the University Hospital of Basel have now discovered a substance that suppresses the formation of metastases. In the journal Cell, the team of molecular biologists, co…

Bedford Day Celebration with Ben Best

Posted by Paul Battista in biotech/medical, cryonics, life extension

Jan 30
2019

Celebrate Bedford Day, a celebration of the first human to be placed into cryonic suspension.

Dr. James Bedford is the oldest person currently in Cryostasis.

On Jan. 12, 1967, James Bedford, a psychology professor at Glendale College in California who had just died of cancer, took his first step toward coming back to life. On that day, the professor became the first person ever frozen in cryonic suspension, embedded in liquid nitrogen at minus-321 degrees Fahrenheit.

Ben Best will give a presentation on:

Continue reading “Bedford Day Celebration with Ben Best” | >

Is empirical testing of string theory possible?

Posted by Paul Battista in quantum physics

Jan 30
2019

Conference at ludwig maximilian university in munich.

New materials could ‘drive wound healing’

Posted by Paul Battista in biotech/medical, materials

Jan 30
2019

Researchers have developed new bioinspired material that interacts with surrounding tissues to promote healing.

Brain Cancer Patient Is First to Get Untested Treatment Under Trump-Backed Law

Posted by Paul Battista in biotech/medical, law, neuroscience

Jan 30
2019

‘Right to Try’ law allows patients and drugmakers to circumvent the FDA’s rules on access to experimental drugs.

Osteoporosis breakthrough: Bone mass increased

Posted by Paul Battista in innovation, neuroscience

Jan 30
2019

A groundbreaking set of studies has found that blocking certain receptors in the brain leads to the growth of remarkably strong bones. Could a new osteoporosis treatment be on the horizon?

A neural network can learn to organize the world it sees into concepts—just like we do

Posted by Paul Battista in information science, robotics/AI

Jan 30
2019

Generative adversarial networks are not just good for causing mischief. They can also show us how AI algorithms “think.”

Gene-editing tool CRISPR repurposed to develop better antibiotics

Posted by Paul Battista in biotech/medical, genetics

Jan 30
2019

A University of Wisconsin-Madison researcher and his collaborators at the University of California, San Francisco have repurposed the gene-editing tool CRISPR to study which genes are targeted by particular antibiotics, providing clues on how to improve existing antibiotics or develop new ones.